AlloVir, Inc. (NASDAQ:ALVR) Short Interest Down 11.1% in October

AlloVir, Inc. (NASDAQ:ALVR) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 4,890,000 shares, a drop of 11.1% from the September 30th total of 5,500,000 shares. Based on an average daily volume of 151,000 shares, the short-interest ratio is presently 32.4 days.

Institutional Investors Weigh In On AlloVir

A number of large investors have recently bought and sold shares of ALVR. Cubist Systematic Strategies LLC increased its stake in AlloVir by 152.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock valued at $36,000 after buying an additional 30,072 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of AlloVir during the 2nd quarter valued at about $55,000. Price T Rowe Associates Inc. MD boosted its stake in shares of AlloVir by 127.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock valued at $74,000 after purchasing an additional 54,900 shares in the last quarter. Marquette Asset Management LLC bought a new position in shares of AlloVir during the first quarter valued at about $135,000. Finally, Acadian Asset Management LLC grew its holdings in shares of AlloVir by 694.6% in the first quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock worth $1,197,000 after purchasing an additional 1,387,666 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

AlloVir Stock Performance

NASDAQ:ALVR opened at $0.89 on Thursday. The firm has a market cap of $102.21 million, a price-to-earnings ratio of -0.72 and a beta of 0.79. The firm’s 50-day simple moving average is $0.79 and its 200 day simple moving average is $0.77. AlloVir has a 52 week low of $0.58 and a 52 week high of $2.49.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. Sell-side analysts anticipate that AlloVir will post -0.5 EPS for the current year.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.